A phase II study of L19IL2 injected directly into the tumor in patients with stage III/IV melanoma

Update Il y a 4 ans
Reference: EUCTR2009-014799-23

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Rate of patients with complete response (CR) of L19IL2 treated metastases at week 12


Inclusion criteria

  • Cancer- Patients with histopathologically-proven malignant melanoma with presence of measurable and injectable dermal or subcutaneous metastases either in clinical stage III or stage IV